Antikoagulačná liečba a zvrátenie jej účinkov

Reversal of antithrombotic agents. (otvorí nové okno)

Bauer KA.

Zdroj‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Označenie‎: PubMed 22460529

Identifikátor digitálneho objektu‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (otvorí nové okno)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (otvorí nové okno)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Zdroj‎: J Thromb Haemost 2015;13(10):1790-8.

Označenie‎: PubMed 26270886

Identifikátor digitálneho objektu‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (otvorí nové okno)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (otvorí nové okno)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Zdroj‎: N Engl J Med 2019;380(14):1326-35.

Označenie‎: PubMed 30730782

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (otvorí nové okno)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (otvorí nové okno)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Zdroj‎: N Engl J Med 2016;375(12):1131-41.

Označenie‎: PubMed 27573206

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (otvorí nové okno)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (otvorí nové okno)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Zdroj‎: Circulation 2011;124(14):1573-9.

Označenie‎: PubMed 21900088

Identifikátor digitálneho objektu‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (otvorí nové okno)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (otvorí nové okno)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Zdroj‎: Lancet 2015;385(9982):2077-87.

Označenie‎: PubMed 25728933

Identifikátor digitálneho objektu‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (otvorí nové okno)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (otvorí nové okno)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Zdroj‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Označenie‎: PubMed 24089118

Identifikátor digitálneho objektu‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (otvorí nové okno)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (otvorí nové okno)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Zdroj‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Označenie‎: PubMed 22473649

Identifikátor digitálneho objektu‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (otvorí nové okno)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (otvorí nové okno)

Levi M, Eerenberg E, Kamphuisen PW.

Zdroj‎: J Thromb Haemost 2011;9(9):1705-12.

Označenie‎: PubMed 21729240

Identifikátor digitálneho objektu‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (otvorí nové okno)

Emergency reversal of warfarin anticoagulation. (otvorí nové okno)

Lin Y, Callum J.

Zdroj‎: CMAJ 2010;182(18):2004.

Označenie‎: PubMed 21078740

Identifikátor digitálneho objektu‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (otvorí nové okno)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (otvorí nové okno)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Zdroj‎: Thromb Haemost 2012;108(2):217-24.

Označenie‎: PubMed 22627883

Identifikátor digitálneho objektu‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (otvorí nové okno)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (otvorí nové okno)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Zdroj‎: J Thromb Haemost 2008;6(4):622-31.

Označenie‎: PubMed 18208533

Identifikátor digitálneho objektu‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (otvorí nové okno)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (otvorí nové okno)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Zdroj‎: Blood Adv 2019;3(2):158-67.

Označenie‎: PubMed 30658963

Identifikátor digitálneho objektu‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (otvorí nové okno)

Idarucizumab for dabigatran reversal. (otvorí nové okno)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Zdroj‎: N Engl J Med 2015;373(6):511-20.

Označenie‎: PubMed 26095746

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (otvorí nové okno)

Idarucizumab for dabigatran reversal - full cohort analysis. (otvorí nové okno)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Zdroj‎: N Engl J Med 2017;377(5):431-41.

Označenie‎: PubMed 28693366

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (otvorí nové okno)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (otvorí nové okno)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Zdroj‎: Blood 2003;102(13):4594-9.

Označenie‎: PubMed 12920042

Identifikátor digitálneho objektu‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (otvorí nové okno)

Role of agents for reversing the effects of target-specific oral anticoagulants. (otvorí nové okno)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Zdroj‎: Am J Health Syst Pharm 2017;74(2):54-61.

Označenie‎: PubMed 27895055

Identifikátor digitálneho objektu‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (otvorí nové okno)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (otvorí nové okno)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Zdroj‎: Anesth Analg 2011;113(4):703-10.

Označenie‎: PubMed 21890888

Identifikátor digitálneho objektu‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (otvorí nové okno)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (otvorí nové okno)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Zdroj‎: J Am Coll Cardiol 2017;70(24):3042-67.

Označenie‎: PubMed 29203195

Identifikátor digitálneho objektu‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (otvorí nové okno)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (otvorí nové okno)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Zdroj‎: World Neurosurg 2014;81(1):110-5.

Označenie‎: PubMed 23220122

Identifikátor digitálneho objektu‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (otvorí nové okno)

Reversal of warfarin-induced hemorrhage in the emergency department. (otvorí nové okno)

Zareh M, Davis A, Henderson S.

Zdroj‎: West J Emerg Med 2011;12(4):386-92.

Označenie‎: PubMed 22224125

Identifikátor digitálneho objektu‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (otvorí nové okno)

INTENZÍVNA STAROSTLIVOSŤ

Antikoagulačná liečba a zvrátenie jej účinkov

slovenčina

Antikoagulačná liečba a zvrátenie jej účinkov

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Antikoagulačná liečba a zvrátenie jej účinkov

Reversal of antithrombotic agents. (otvorí nové okno)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (otvorí nové okno)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (otvorí nové okno)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (otvorí nové okno)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (otvorí nové okno)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (otvorí nové okno)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (otvorí nové okno)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (otvorí nové okno)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (otvorí nové okno)

Emergency reversal of warfarin anticoagulation. (otvorí nové okno)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (otvorí nové okno)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (otvorí nové okno)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (otvorí nové okno)

Idarucizumab for dabigatran reversal. (otvorí nové okno)

Idarucizumab for dabigatran reversal - full cohort analysis. (otvorí nové okno)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (otvorí nové okno)

Role of agents for reversing the effects of target-specific oral anticoagulants. (otvorí nové okno)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (otvorí nové okno)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (otvorí nové okno)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (otvorí nové okno)

Reversal of warfarin-induced hemorrhage in the emergency department. (otvorí nové okno)

Výbor pre styk s nemocnicami (VSN)

Informačné balíčky pre lekárov

Videá

Antikoagulačná liečba a zvrátenie jej účinkov

Vyberte si jazyk

Poslať odkaz